VMI
SYRE icon

VHCP Management II’s Spyre Therapeutics SYRE Stock Holding History

VHCP Management II’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,005
Closed -$1.52M – 22
2016
Q4 		$1.52M Hold
14,005
– – 0.73% 19
2016
Q3 		$2.23M Hold
14,005
– – 1.15% 20
2016
Q2 		$1.53M Buy
+14,005
New +$2.68M 0.92% 19

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

VHCP Management II's SYRE Position: Q1 2017 in Review

VHCP Management II sold out of Spyre Therapeutics (SYRE) in Q1 2017, closing a stake of 14,005 shares — an estimated $1.52M sold.

VHCP Management II first reported a position in SYRE in Q2 2016 and held it in 3 quarters. The position peaked at $2.23M in Q3 2016. 23 funds tracked by Wall St. Rank hold SYRE as of Q1 2017.

  • VHCP Management II reported no remaining Spyre Therapeutics position as of Q1 2017 after selling out during the quarter.
  • VHCP Management II sold 14,005 Spyre Therapeutics shares in Q1 2017, an estimated $1.52M.
  • VHCP Management II first reported a position in Spyre Therapeutics in Q2 2016 and held it in 3 quarters.
  • VHCP Management II's Spyre Therapeutics position peaked at $2.23M in Q3 2016.
  • 23 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2017.

Based on VHCP Management II's 13F filing for Q1 2017, filed 12 May 2017.